{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.666.5.2349","meta":{"versionId":"12","lastUpdated":"2016-03-31T01:00:12.000-04:00"},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">\n      <h2>Immunocompromised Therapies I10</h2>\n      <p>This value set includes codes from the following code systems:</p>\n      <ul>\n        <li>Include these codes as defined in \n          <code>http://www.icd10data.com/icd10pcs</code>\n          <table class=\"none\">\n            <tr>\n              <td>\n                <b>Code</b>\n              </td>\n              <td>\n                <b>Display</b>\n              </td>\n            </tr>\n            <tr>\n              <td>3E00X05</td>\n              <td>Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E00X0M</td>\n              <td>Introduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E01305</td>\n              <td>Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0130M</td>\n              <td>Introduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E02305</td>\n              <td>Introduction of Other Antineoplastic into Muscle, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0230M</td>\n              <td>Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E03002</td>\n              <td>Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E03003</td>\n              <td>Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E03005</td>\n              <td>Introduction of Other Antineoplastic into Peripheral Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0300M</td>\n              <td>Introduction of Monoclonal Antibody into Peripheral Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0300P</td>\n              <td>Introduction of Clofarabine into Peripheral Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E03302</td>\n              <td>Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E03303</td>\n              <td>Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E03305</td>\n              <td>Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0330M</td>\n              <td>Introduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0330P</td>\n              <td>Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E04002</td>\n              <td>Introduction of High-dose Interleukin-2 into Central Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E04003</td>\n              <td>Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E04005</td>\n              <td>Introduction of Other Antineoplastic into Central Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0400M</td>\n              <td>Introduction of Monoclonal Antibody into Central Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0400P</td>\n              <td>Introduction of Clofarabine into Central Vein, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E04302</td>\n              <td>Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E04303</td>\n              <td>Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E04305</td>\n              <td>Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0430M</td>\n              <td>Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0430P</td>\n              <td>Introduction of Clofarabine into Central Vein, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E05002</td>\n              <td>Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E05003</td>\n              <td>Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E05005</td>\n              <td>Introduction of Other Antineoplastic into Peripheral Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0500M</td>\n              <td>Introduction of Monoclonal Antibody into Peripheral Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0500P</td>\n              <td>Introduction of Clofarabine into Peripheral Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E05302</td>\n              <td>Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E05303</td>\n              <td>Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E05305</td>\n              <td>Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0530M</td>\n              <td>Introduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0530P</td>\n              <td>Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E06002</td>\n              <td>Introduction of High-dose Interleukin-2 into Central Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E06003</td>\n              <td>Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E06005</td>\n              <td>Introduction of Other Antineoplastic into Central Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0600M</td>\n              <td>Introduction of Monoclonal Antibody into Central Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0600P</td>\n              <td>Introduction of Clofarabine into Central Artery, Open Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E06302</td>\n              <td>Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E06303</td>\n              <td>Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E06305</td>\n              <td>Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0630M</td>\n              <td>Introduction of Monoclonal Antibody into Central Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0630P</td>\n              <td>Introduction of Clofarabine into Central Artery, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E09305</td>\n              <td>Introduction of Other Antineoplastic into Nose, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0930M</td>\n              <td>Introduction of Monoclonal Antibody into Nose, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E09705</td>\n              <td>Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0970M</td>\n              <td>Introduction of Monoclonal Antibody into Nose, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E09X05</td>\n              <td>Introduction of Other Antineoplastic into Nose, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E09X0M</td>\n              <td>Introduction of Monoclonal Antibody into Nose, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0A305</td>\n              <td>Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0A30M</td>\n              <td>Introduction of Monoclonal Antibody into Bone Marrow, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0B305</td>\n              <td>Introduction of Other Antineoplastic into Ear, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0B30M</td>\n              <td>Introduction of Monoclonal Antibody into Ear, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0B705</td>\n              <td>Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0B70M</td>\n              <td>Introduction of Monoclonal Antibody into Ear, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0BX05</td>\n              <td>Introduction of Other Antineoplastic into Ear, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0BX0M</td>\n              <td>Introduction of Monoclonal Antibody into Ear, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0C305</td>\n              <td>Introduction of Other Antineoplastic into Eye, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0C30M</td>\n              <td>Introduction of Monoclonal Antibody into Eye, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0C705</td>\n              <td>Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0C70M</td>\n              <td>Introduction of Monoclonal Antibody into Eye, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0CX05</td>\n              <td>Introduction of Other Antineoplastic into Eye, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0CX0M</td>\n              <td>Introduction of Monoclonal Antibody into Eye, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0D305</td>\n              <td>Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0D30M</td>\n              <td>Introduction of Monoclonal Antibody into Mouth and Pharynx, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0D705</td>\n              <td>Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0D70M</td>\n              <td>Introduction of Monoclonal Antibody into Mouth and Pharynx, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0DX05</td>\n              <td>Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0DX0M</td>\n              <td>Introduction of Monoclonal Antibody into Mouth and Pharynx, External Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0E305</td>\n              <td>Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0E30M</td>\n              <td>Introduction of Monoclonal Antibody into Products of Conception, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0E705</td>\n              <td>Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0E70M</td>\n              <td>Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0E805</td>\n              <td>Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0E80M</td>\n              <td>Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0F305</td>\n              <td>Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0F30M</td>\n              <td>Introduction of Monoclonal Antibody into Respiratory Tract, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0F705</td>\n              <td>Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0F70M</td>\n              <td>Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0F805</td>\n              <td>Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0F80M</td>\n              <td>Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0G305</td>\n              <td>Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0G30M</td>\n              <td>Introduction of Monoclonal Antibody into Upper GI, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0G705</td>\n              <td>Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0G70M</td>\n              <td>Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0G805</td>\n              <td>Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0G80M</td>\n              <td>Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0H305</td>\n              <td>Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0H30M</td>\n              <td>Introduction of Monoclonal Antibody into Lower GI, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0H705</td>\n              <td>Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0H70M</td>\n              <td>Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0H805</td>\n              <td>Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0H80M</td>\n              <td>Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0J305</td>\n              <td>Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0J30M</td>\n              <td>Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0J705</td>\n              <td>Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0J70M</td>\n              <td>Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0J805</td>\n              <td>Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0J80M</td>\n              <td>Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0K305</td>\n              <td>Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0K30M</td>\n              <td>Introduction of Monoclonal Antibody into Genitourinary Tract, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0K705</td>\n              <td>Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0K70M</td>\n              <td>Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0K805</td>\n              <td>Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0K80M</td>\n              <td>Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0L305</td>\n              <td>Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0L30M</td>\n              <td>Introduction of Monoclonal Antibody into Pleural Cavity, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0L705</td>\n              <td>Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0L70M</td>\n              <td>Introduction of Monoclonal Antibody into Pleural Cavity, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0M305</td>\n              <td>Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0M30M</td>\n              <td>Introduction of Monoclonal Antibody into Peritoneal Cavity, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0M705</td>\n              <td>Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0M70M</td>\n              <td>Introduction of Monoclonal Antibody into Peritoneal Cavity, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0N305</td>\n              <td>Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0N30M</td>\n              <td>Introduction of Monoclonal Antibody into Male Reproductive, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0N705</td>\n              <td>Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0N70M</td>\n              <td>Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0N805</td>\n              <td>Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0N80M</td>\n              <td>Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0P305</td>\n              <td>Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0P30M</td>\n              <td>Introduction of Monoclonal Antibody into Female Reproductive, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0P705</td>\n              <td>Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0P70M</td>\n              <td>Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0P805</td>\n              <td>Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0P80M</td>\n              <td>Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening Endoscopic</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0Q305</td>\n              <td>Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0Q30M</td>\n              <td>Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0Q705</td>\n              <td>Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0Q70M</td>\n              <td>Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0R302</td>\n              <td>Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0R303</td>\n              <td>Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0R305</td>\n              <td>Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0R30M</td>\n              <td>Introduction of Monoclonal Antibody into Spinal Canal, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0S302</td>\n              <td>Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0S303</td>\n              <td>Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0S305</td>\n              <td>Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0S30M</td>\n              <td>Introduction of Monoclonal Antibody into Epidural Space, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0U305</td>\n              <td>Introduction of Other Antineoplastic into Joints, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0U30M</td>\n              <td>Introduction of Monoclonal Antibody into Joints, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0V305</td>\n              <td>Introduction of Other Antineoplastic into Bones, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0V30M</td>\n              <td>Introduction of Monoclonal Antibody into Bones, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0W305</td>\n              <td>Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0W30M</td>\n              <td>Introduction of Monoclonal Antibody into Lymphatics, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0Y305</td>\n              <td>Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0Y30M</td>\n              <td>Introduction of Monoclonal Antibody into Pericardial Cavity, Percutaneous Approach</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0Y705</td>\n              <td>Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E0Y70M</td>\n              <td>Introduction of Monoclonal Antibody into Pericardial Cavity, Via Natural or Artificial Opening</td>\n              <td/>\n            </tr>\n          </table>\n        </li>\n      </ul>\n    </div>"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2349","version":"20160331","name":"Immunocompromised Therapies I10","status":"active","date":"2016-03-31T01:00:12-04:00","publisher":"Lantana EH Steward","compose":{"include":[{"system":"http://www.icd10data.com/icd10pcs","concept":[{"code":"3E00X05","display":"Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach"},{"code":"3E00X0M","display":"Introduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach"},{"code":"3E01305","display":"Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach"},{"code":"3E0130M","display":"Introduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach"},{"code":"3E02305","display":"Introduction of Other Antineoplastic into Muscle, Percutaneous Approach"},{"code":"3E0230M","display":"Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach"},{"code":"3E03002","display":"Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach"},{"code":"3E03003","display":"Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach"},{"code":"3E03005","display":"Introduction of Other Antineoplastic into Peripheral Vein, Open Approach"},{"code":"3E0300M","display":"Introduction of Monoclonal Antibody into Peripheral Vein, Open Approach"},{"code":"3E0300P","display":"Introduction of Clofarabine into Peripheral Vein, Open Approach"},{"code":"3E03302","display":"Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach"},{"code":"3E03303","display":"Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach"},{"code":"3E03305","display":"Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach"},{"code":"3E0330M","display":"Introduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach"},{"code":"3E0330P","display":"Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach"},{"code":"3E04002","display":"Introduction of High-dose Interleukin-2 into Central Vein, Open Approach"},{"code":"3E04003","display":"Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach"},{"code":"3E04005","display":"Introduction of Other Antineoplastic into Central Vein, Open Approach"},{"code":"3E0400M","display":"Introduction of Monoclonal Antibody into Central Vein, Open Approach"},{"code":"3E0400P","display":"Introduction of Clofarabine into Central Vein, Open Approach"},{"code":"3E04302","display":"Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach"},{"code":"3E04303","display":"Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach"},{"code":"3E04305","display":"Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach"},{"code":"3E0430M","display":"Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach"},{"code":"3E0430P","display":"Introduction of Clofarabine into Central Vein, Percutaneous Approach"},{"code":"3E05002","display":"Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach"},{"code":"3E05003","display":"Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach"},{"code":"3E05005","display":"Introduction of Other Antineoplastic into Peripheral Artery, Open Approach"},{"code":"3E0500M","display":"Introduction of Monoclonal Antibody into Peripheral Artery, Open Approach"},{"code":"3E0500P","display":"Introduction of Clofarabine into Peripheral Artery, Open Approach"},{"code":"3E05302","display":"Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach"},{"code":"3E05303","display":"Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach"},{"code":"3E05305","display":"Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach"},{"code":"3E0530M","display":"Introduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach"},{"code":"3E0530P","display":"Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach"},{"code":"3E06002","display":"Introduction of High-dose Interleukin-2 into Central Artery, Open Approach"},{"code":"3E06003","display":"Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach"},{"code":"3E06005","display":"Introduction of Other Antineoplastic into Central Artery, Open Approach"},{"code":"3E0600M","display":"Introduction of Monoclonal Antibody into Central Artery, Open Approach"},{"code":"3E0600P","display":"Introduction of Clofarabine into Central Artery, Open Approach"},{"code":"3E06302","display":"Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach"},{"code":"3E06303","display":"Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach"},{"code":"3E06305","display":"Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach"},{"code":"3E0630M","display":"Introduction of Monoclonal Antibody into Central Artery, Percutaneous Approach"},{"code":"3E0630P","display":"Introduction of Clofarabine into Central Artery, Percutaneous Approach"},{"code":"3E09305","display":"Introduction of Other Antineoplastic into Nose, Percutaneous Approach"},{"code":"3E0930M","display":"Introduction of Monoclonal Antibody into Nose, Percutaneous Approach"},{"code":"3E09705","display":"Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening"},{"code":"3E0970M","display":"Introduction of Monoclonal Antibody into Nose, Via Natural or Artificial Opening"},{"code":"3E09X05","display":"Introduction of Other Antineoplastic into Nose, External Approach"},{"code":"3E09X0M","display":"Introduction of Monoclonal Antibody into Nose, External Approach"},{"code":"3E0A305","display":"Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach"},{"code":"3E0A30M","display":"Introduction of Monoclonal Antibody into Bone Marrow, Percutaneous Approach"},{"code":"3E0B305","display":"Introduction of Other Antineoplastic into Ear, Percutaneous Approach"},{"code":"3E0B30M","display":"Introduction of Monoclonal Antibody into Ear, Percutaneous Approach"},{"code":"3E0B705","display":"Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening"},{"code":"3E0B70M","display":"Introduction of Monoclonal Antibody into Ear, Via Natural or Artificial Opening"},{"code":"3E0BX05","display":"Introduction of Other Antineoplastic into Ear, External Approach"},{"code":"3E0BX0M","display":"Introduction of Monoclonal Antibody into Ear, External Approach"},{"code":"3E0C305","display":"Introduction of Other Antineoplastic into Eye, Percutaneous Approach"},{"code":"3E0C30M","display":"Introduction of Monoclonal Antibody into Eye, Percutaneous Approach"},{"code":"3E0C705","display":"Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening"},{"code":"3E0C70M","display":"Introduction of Monoclonal Antibody into Eye, Via Natural or Artificial Opening"},{"code":"3E0CX05","display":"Introduction of Other Antineoplastic into Eye, External Approach"},{"code":"3E0CX0M","display":"Introduction of Monoclonal Antibody into Eye, External Approach"},{"code":"3E0D305","display":"Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach"},{"code":"3E0D30M","display":"Introduction of Monoclonal Antibody into Mouth and Pharynx, Percutaneous Approach"},{"code":"3E0D705","display":"Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening"},{"code":"3E0D70M","display":"Introduction of Monoclonal Antibody into Mouth and Pharynx, Via Natural or Artificial Opening"},{"code":"3E0DX05","display":"Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach"},{"code":"3E0DX0M","display":"Introduction of Monoclonal Antibody into Mouth and Pharynx, External Approach"},{"code":"3E0E305","display":"Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach"},{"code":"3E0E30M","display":"Introduction of Monoclonal Antibody into Products of Conception, Percutaneous Approach"},{"code":"3E0E705","display":"Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening"},{"code":"3E0E70M","display":"Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening"},{"code":"3E0E805","display":"Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0E80M","display":"Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0F305","display":"Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach"},{"code":"3E0F30M","display":"Introduction of Monoclonal Antibody into Respiratory Tract, Percutaneous Approach"},{"code":"3E0F705","display":"Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening"},{"code":"3E0F70M","display":"Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening"},{"code":"3E0F805","display":"Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0F80M","display":"Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0G305","display":"Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach"},{"code":"3E0G30M","display":"Introduction of Monoclonal Antibody into Upper GI, Percutaneous Approach"},{"code":"3E0G705","display":"Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening"},{"code":"3E0G70M","display":"Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening"},{"code":"3E0G805","display":"Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0G80M","display":"Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0H305","display":"Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach"},{"code":"3E0H30M","display":"Introduction of Monoclonal Antibody into Lower GI, Percutaneous Approach"},{"code":"3E0H705","display":"Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening"},{"code":"3E0H70M","display":"Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening"},{"code":"3E0H805","display":"Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0H80M","display":"Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0J305","display":"Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach"},{"code":"3E0J30M","display":"Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Percutaneous Approach"},{"code":"3E0J705","display":"Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening"},{"code":"3E0J70M","display":"Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening"},{"code":"3E0J805","display":"Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0J80M","display":"Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0K305","display":"Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach"},{"code":"3E0K30M","display":"Introduction of Monoclonal Antibody into Genitourinary Tract, Percutaneous Approach"},{"code":"3E0K705","display":"Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening"},{"code":"3E0K70M","display":"Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening"},{"code":"3E0K805","display":"Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0K80M","display":"Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0L305","display":"Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach"},{"code":"3E0L30M","display":"Introduction of Monoclonal Antibody into Pleural Cavity, Percutaneous Approach"},{"code":"3E0L705","display":"Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening"},{"code":"3E0L70M","display":"Introduction of Monoclonal Antibody into Pleural Cavity, Via Natural or Artificial Opening"},{"code":"3E0M305","display":"Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach"},{"code":"3E0M30M","display":"Introduction of Monoclonal Antibody into Peritoneal Cavity, Percutaneous Approach"},{"code":"3E0M705","display":"Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening"},{"code":"3E0M70M","display":"Introduction of Monoclonal Antibody into Peritoneal Cavity, Via Natural or Artificial Opening"},{"code":"3E0N305","display":"Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach"},{"code":"3E0N30M","display":"Introduction of Monoclonal Antibody into Male Reproductive, Percutaneous Approach"},{"code":"3E0N705","display":"Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening"},{"code":"3E0N70M","display":"Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening"},{"code":"3E0N805","display":"Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0N80M","display":"Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0P305","display":"Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach"},{"code":"3E0P30M","display":"Introduction of Monoclonal Antibody into Female Reproductive, Percutaneous Approach"},{"code":"3E0P705","display":"Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening"},{"code":"3E0P70M","display":"Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening"},{"code":"3E0P805","display":"Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0P80M","display":"Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening Endoscopic"},{"code":"3E0Q305","display":"Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach"},{"code":"3E0Q30M","display":"Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Percutaneous Approach"},{"code":"3E0Q705","display":"Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening"},{"code":"3E0Q70M","display":"Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Via Natural or Artificial Opening"},{"code":"3E0R302","display":"Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach"},{"code":"3E0R303","display":"Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach"},{"code":"3E0R305","display":"Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach"},{"code":"3E0R30M","display":"Introduction of Monoclonal Antibody into Spinal Canal, Percutaneous Approach"},{"code":"3E0S302","display":"Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach"},{"code":"3E0S303","display":"Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach"},{"code":"3E0S305","display":"Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach"},{"code":"3E0S30M","display":"Introduction of Monoclonal Antibody into Epidural Space, Percutaneous Approach"},{"code":"3E0U305","display":"Introduction of Other Antineoplastic into Joints, Percutaneous Approach"},{"code":"3E0U30M","display":"Introduction of Monoclonal Antibody into Joints, Percutaneous Approach"},{"code":"3E0V305","display":"Introduction of Other Antineoplastic into Bones, Percutaneous Approach"},{"code":"3E0V30M","display":"Introduction of Monoclonal Antibody into Bones, Percutaneous Approach"},{"code":"3E0W305","display":"Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach"},{"code":"3E0W30M","display":"Introduction of Monoclonal Antibody into Lymphatics, Percutaneous Approach"},{"code":"3E0Y305","display":"Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach"},{"code":"3E0Y30M","display":"Introduction of Monoclonal Antibody into Pericardial Cavity, Percutaneous Approach"},{"code":"3E0Y705","display":"Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening"},{"code":"3E0Y70M","display":"Introduction of Monoclonal Antibody into Pericardial Cavity, Via Natural or Artificial Opening"}]}]}}